Prelude Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-111,468
| Closed | -$4.48M | – | 1240 |
|
|
2026
Q1 | $4.48M | Buy |
111,468
+72,947
| +189% | +$1.57M | 0.34% | 65 |
|
|
2025
Q4 | $968K | Buy |
+38,521
| New | +$904K | 0.07% | 321 |
|
|
2025
Q3 | – | Sell |
-31,139
| Closed | -$539K | – | 1137 |
|
|
2025
Q2 | $539K | Buy |
+31,139
| New | +$576K | 0.05% | 417 |
|
|
2025
Q1 | – | Sell |
-31,255
| Closed | -$997K | – | 1176 |
|
|
2024
Q4 | $997K | Buy |
31,255
+2,300
| +8% | +$69.2K | 0.06% | 379 |
|
|
2024
Q3 | $835K | Buy |
28,955
+16,021
| +124% | +$593K | 0.05% | 436 |
|
|
2024
Q2 | $496K | Buy |
+12,934
| New | +$586K | 0.03% | 549 |
|
|
2024
Q1 | – | Sell |
-8,240
| Closed | -$493K | – | 1300 |
|
|
2023
Q4 | $493K | Buy |
+8,240
| New | +$418K | 0.03% | 522 |
|
|
2023
Q3 | – | Sell |
-2,861
| Closed | -$261K | – | 1125 |
|
|
2023
Q2 | $261K | Buy |
+2,861
| New | +$247K | 0.02% | 710 |
|
|
2022
Q4 | – | Sell |
-11,293
| Closed | -$771K | – | 1319 |
|
|
2022
Q3 | $771K | Buy |
+11,293
| New | +$668K | 0.03% | 500 |
|
|
2021
Q3 | – | Sell |
-4,434
| Closed | -$280K | – | 1719 |
|
|
2021
Q2 | $280K | Sell |
4,434
-10,957
| -71% | -$565K | 0.01% | 1228 |
|
|
2021
Q1 | $660K | Buy |
+15,391
| New | +$728K | 0.02% | 773 |
|
|
2020
Q3 | – | Sell |
-3,956
| Closed | -$129K | – | 1796 |
|
|
2020
Q2 | $129K | Buy |
3,956
+448
| +13% | +$14.4K | 0.01% | 866 |
|
|
2020
Q1 | $94K | Buy |
+3,508
| New | +$125K | 0.01% | 605 |
|
|
2019
Q1 | – | Sell |
-11,790
| Closed | -$156K | – | 1745 |
|
|
2018
Q4 | $156K | Buy |
+11,790
| New | +$181K | 0.01% | 807 |
|
Other funds holding APLS
Prelude Capital Management's APLS Position: Q2 2026 in Review
Prelude Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 111,468 shares — an estimated $4.48M sold.
Prelude Capital Management first reported a position in APLS in Q4 2018 and held it in 14 quarters. The position peaked at $4.48M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Prelude Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Prelude Capital Management sold 111,468 Apellis Pharmaceuticals shares in Q2 2026, an estimated $4.48M.
- Prelude Capital Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 14 quarters.
- Prelude Capital Management's Apellis Pharmaceuticals position peaked at $4.48M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.